Journey Medical Q2 FY26 GAAP net loss narrows to $0.3 million; revenue rises 23% to $18.5 million year over year - DERM News | RalliesJourney Medical Q2 FY26 GAAP net loss narrows to $0.3 million; revenue rises 23% to $18.5 million year over year
D
DERM• Q2 revenue and loss improve year over year
- Journey Medical posted Q2 2026 revenue of USD 18.5 million, up 23% from the prior-year quarter.
- GAAP net loss narrowed to USD 312,000, or USD 0.01 per share, from USD 3.8 million, or USD 0.16 per share.
- Emrosi revenue reached USD 8.1 million; total prescriptions were about 36,000, up from about 30,000 in Q1 2026.
- Selling, general and administrative expense fell to USD 10.9 million, down USD 1 million on lower Emrosi launch-related spending.
- Claude Maraoui cited rising prescription demand and payer coverage for Emrosi, with cash and equivalents at USD 25.6 million.
•
